NASDAQ$DYN
Dyne Therapeutics Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Reported financial results for the fourth quarter and full year 2022 and business highlights.
Dyne Therapeutics reported a net loss of $38.8 million for the quarter ended December 31, 2022, with cash, cash equivalents, and marketable securities totaling $256.0 million, expected to fund operations through 2024.
- Enrollment continues in ACHIEVE, a Phase 1/2 global clinical trial evaluating DYNE-101 in adult patients with myotonic dystrophy type 1 (DM1).
- Enrollment continues in DELIVER, a Phase 1/2 global clinical trial evaluating DYNE-251 in males with Duchenne muscular dystrophy (DMD) who have mutations amenable to exon 51 skipping therapy.
- Dyne anticipates reporting initial data in the second half of 2023 from the ACHIEVE trial of DYNE-101 in DM1 on safety, tolerability and splicing.
- Dyne anticipates reporting initial data in the second half of 2023 from the DELIVER trial of DYNE-251 in DMD on safety, tolerability and dystrophin.
Headline financials
Revenue & EPS history
Dyne Therapeutics · Revenue · Quarterly
$0
Forward guidance
Dyne anticipates reporting initial data in the second half of 2023 from the ACHIEVE trial of DYNE-101 in DM1 and the DELIVER trial of DYNE-251 in DMD. Cash position is expected to fund operations through 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
+1.8%
Avg return
Earnings day
-2.5%
Avg return
5 days after
+3.0%
Avg return
30 days after
59%
13 / 22 earnings
Positive
+21.3%
Q3 2024
Best reaction
-6.5%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +3.6% | -4.9% | +15.9% | |
| Q3 2025 | -2.8% | -14.0% | -5.8% | |
| Q2 2025 | -1.3% | +7.9% | +47.7% | |
| Q1 2025 | +1.1% | +3.6% | +30.1% | |
| Q4 2024 | -4.5% | -13.8% | -17.0% | |
| Q3 2024 | +21.3% | +0.9% | -9.0% | |
| Q2 2024 | +0.5% | +5.7% | -22.0% | |
| Q1 2024 | +1.0% | -0.7% | +23.4% | |
| Q4 2023 | -3.4% | -9.2% | -4.5% | |
| Q3 2023 | +6.5% | +24.3% | +66.0% | |
| Q2 2023 | -1.8% | -15.6% | +0.1% | |
| Q1 2023 | -4.0% | -4.6% | -7.4% | |
| Q4 2022 | +10.1% | +8.3% | -15.5% | |
| Q3 2022 | +1.6% | -4.9% | +15.8% | |
| Q2 2022 | +4.3% | +1.1% | +1.0% | |
| Q1 2022 | +10.5% | -16.4% | -45.0% | |
| Q4 2021 | -1.7% | -2.9% | +16.5% | |
| Q3 2021 | +2.0% | +0.7% | -10.4% | |
| Q2 2021 | +3.3% | -4.1% | -9.6% | |
| Q1 2021 | +5.1% | +0.2% | +1.9% | |
| Q4 2020 | -6.5% | -6.2% | -4.4% | |
| Q3 2020 | -5.0% | -9.6% | -1.5% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro